RESUMO
BACKGROUND AND OBJECTIVE: Cyclooxygenase (COX) is an enzyme that converts arachidonic acid to prostanoids. There are two isoforms of COX, namely COX-1 and COX-2. COX-2 is highly inducible by several stimuli and is associated with inflammation. Recent studies have shown that COX-2 is upregulated in the airway epithelium of patients with asthma but little is known about the role it plays in cough, a common symptom of bronchial asthma. This study was designed to investigate the role of COX-2 in cough reflex sensitivity in patients with asthma. PATIENTS AND METHODS: The effect of etodolac, a potent COX-2 inhibitor, on cough response to inhaled capsaicin was examined in 17 patients with stable asthma in a randomized, placebo-controlled crossover study. Capsaicin cough threshold, defined as the lowest concentration of capsaicin eliciting 5 or more coughs, was measured as an index of airway cough reflex sensitivity. RESULTS: The geometric mean (geometric SEM) cough threshold was significantly increased after a 2-week treatment program with oral etodolac (200 mg twice a day) compared with placebo (36.7 [1.2] vs 21.6 [1.2] gM, P<.02). CONCLUSIONS: These findings indicate that COX-2 may be a possible modulator augmenting airway cough reflex sensitivity in asthmatic airways.
Assuntos
Asma/enzimologia , Tosse/enzimologia , Ciclo-Oxigenase 2/imunologia , Inibidores de Ciclo-Oxigenase/farmacologia , Etodolac/farmacologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Asma/tratamento farmacológico , Asma/imunologia , Capsaicina/imunologia , Tosse/tratamento farmacológico , Tosse/imunologia , Estudos Cross-Over , Inibidores de Ciclo-Oxigenase/uso terapêutico , Interações Medicamentosas , Etodolac/uso terapêutico , Feminino , Volume Expiratório Forçado , Humanos , Masculino , Pessoa de Meia-Idade , Estatísticas não Paramétricas , Capacidade VitalRESUMO
AIM: The aim of this study is to establish a monitoring method to prevent Epstein-Barr virus (EBV)-associated symptoms including post-transplant lymphoproliferative disorder (PTLD) that occur after pediatric renal transplantation. SUBJECTS AND METHODS: Circulating EBV loads were quantified by real-time PCR every 1 - 3 months after grafting in 22 pediatric recipients (13 EBV-seronegative [R(-)] and 9 EBV-seropositive [R(+)] recipients before grafting). The peripheral blood cell populations of non-specific activated killer cells (CD8+HLA-DR+ phenotype) in 13 R(-) recipients and EBV-specific cytotoxic T cells (CTLs) reactive with a tetramer expressing HLA-A24-restricted EBV-specific antigens in 8 of 13 R(-) recipients were determined by flow cytometry. RESULTS: EBV-associated symptoms including PTLD (2 cases) were found in 4 R(-) and none of the R(+) recipients. The maximum of EBV load in the R(-) group was significantly higher that in the R(+) group. In R(-) recipients, 4 symptomatic cases had significantly more EBV genome than asymptomatic cases. EBV-specific CTLs were detected in 6 of the 8 R(-) recipients, but these CTLs could not be detected in 1 of the 2 cases at onset of PTLD. The percentage of CD8+HLA-DR+ cells was significantly higher in asymptomatic recipients than in recipients with EBV-associated symptoms whose EBV loads were over 400 copies/microg DNA. CONCLUSION: Monitoring of killer T cells and EBV loads may allow assessment of the risk of EBV-associated symptoms, and high EBV loads and low EBV-specific and/or non-specific CTL responses may be predictive for development of EBV-associated symptoms such as PTLD.
Assuntos
Infecções por Vírus Epstein-Barr/prevenção & controle , Rejeição de Enxerto/prevenção & controle , Herpesvirus Humano 4/isolamento & purificação , Transplante de Rim , Células T Matadoras Naturais/patologia , Adolescente , Anticorpos Antivirais/análise , Criança , Pré-Escolar , DNA Viral/análise , Infecções por Vírus Epstein-Barr/imunologia , Infecções por Vírus Epstein-Barr/virologia , Feminino , Seguimentos , Rejeição de Enxerto/imunologia , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/imunologia , Humanos , Imunossupressores/uso terapêutico , Masculino , Células T Matadoras Naturais/imunologia , Reação em Cadeia da Polimerase , Prognóstico , Estudos Retrospectivos , Carga ViralRESUMO
Although acute upper respiratory diseases (AURDs) such as common cold and influenza are common, few interventions have been proven to be effective in their prevention and treatment. The aim of this study was to assess the efficacy of ambroxol for preventing AURD. Fifty-four patients were randomly divided into 3 groups: a rebamipide (non-mucoactive drug) group (300 mg/day), carbocisteine group (1500 mg/day) and ambroxol group (45 mg/day). The study was divided into 2 terms, the first half-year (summer season) and the second half-year (winter season). In the preceding winter, only 19.5% of the patients had been vaccinated against influenza viruses (flu). The primary goal of this study was to evaluate the effectiveness of mucoactive drugs in decreasing the frequency of AURD. Treatment with ambroxol, but not carbocisteine, significantly reduced the median number of AURD episodes (P=0.0049 vs. rebamipide). Thirty-three patients without vaccination against flu were assessed especially during the second half-year. Treatment with ambroxol also significantly reduced the median number of AURD episodes in this assessment (P=0.0028 vs. rebamipide in the second half-year). In conclusion, ambroxol may be useful for preventing AURD.
Assuntos
Ambroxol/uso terapêutico , Infecções Respiratórias/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Alanina/análogos & derivados , Alanina/uso terapêutico , Carbocisteína/uso terapêutico , Feminino , Humanos , Masculino , Quinolonas/uso terapêuticoRESUMO
BACKGROUND: Indoor formaldehyde (FA) might worsen allergies and be an underlying factor for the increasing incidence and severity of asthma; the exact mechanism, however, remains unclear. OBJECTIVE: The present study examined the effects of repeated exposure to FA on methacholine- and antigen-induced bronchoconstriction in guinea-pigs in vivo. METHODS: First, non-sensitized guinea-pigs were transnasally treated with 0.1 or 1.0% FA or saline three times a week for 6 weeks, and increasing concentrations of methacholine (50, 100, and 200 microg/mL) were inhaled at 5-min intervals. Second, guinea-pigs pre-treated with transnasal administration of FA or saline using the same protocol were passively sensitized with anti-ovalbumin (OA) serum 7 days before antigen challenge. Third, guinea-pigs were actively sensitized with OA and pre-treated with transnasal administration of FA or saline using the same protocol. The lateral pressure of the tracheal tube (Pao) was measured under anesthesia and artificial ventilation. RESULTS: The antigen-induced increase in Pao in actively sensitized guinea-pigs was significantly potentiated by FA exposure in a dose-dependent manner. The dose-response curve of the methacholine-induced increase in Pao in non-sensitized guinea-pigs or of the antigen-induced increase in Pao in passively sensitized guinea-pigs was not altered by FA exposure. Transnasal administration of FA significantly increased the serum anti-OA homocytotropic antibody titre (IgG) as measured by the passive cutaneous anaphylaxis reaction in actively sensitized guinea-pigs. CONCLUSION: The results suggest that repeated exposure to FA worsens allergic bronchoconstriction through enhancing antigen sensitization.
Assuntos
Fixadores/toxicidade , Formaldeído/toxicidade , Hipersensibilidade/imunologia , Alérgenos , Animais , Anticorpos/sangue , Hiper-Reatividade Brônquica/induzido quimicamente , Broncoconstritores , Cobaias , Imunoglobulina E/sangue , Imunoglobulina G/sangue , Masculino , Cloreto de Metacolina , Ovalbumina/imunologia , Anafilaxia Cutânea PassivaRESUMO
To evaluate the role of protein kinase C in central muscarinic mechanisms regulating voiding, cystometry was performed in conscious rats. Oxotremorine methiodide, a muscarinic agonist was injected i.c.v. in a dose (0.1 microg/rat) shown previously to alter voiding function. Oxotremorine methiodide was also tested after i.c.v. injection of chelerythrine chloride (a protein kinase C inhibitor, 2 microg/rat) or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7, a protein kinase inhibitor, 5 nmol/rat). In untreated rats, oxotremorine methiodide elicited a bimodal response consisting of an initial increase in bladder capacity, maximal voiding pressure, pressure threshold and post voiding intravesical pressure, but reduced voiding efficiency and bladder compliance. The second response consisted of a decrease in bladder capacity and bladder compliance, increases in maximal voiding pressure and post voiding intravesical pressure, but no change in pressure threshold or voiding efficiency. However, approximately 20 min after pre-treatment with chelerythrine chloride or H-7 in doses that did not alter voiding function, oxotremorine methiodide decreased bladder capacity, increased maximal voiding pressure, but did not change pressure threshold or voiding efficiency. These results indicate that inhibitory and facilitatory muscarinic mechanisms in the brain that control voiding function involve different second messenger systems. Inhibitory mechanisms which are blocked by chelerythrine chloride or H-7 must involve protein kinase C and normally be inactive because the protein kinase inhibitors alone did not alter voiding. On the other hand, facilitatory muscarinic mechanisms which previous studies showed were tonically active are not mediated by chelerythrine chloride or H-7 sensitive signaling pathways.
Assuntos
Inibição Neural/fisiologia , Proteína Quinase C/metabolismo , Receptores Muscarínicos/metabolismo , Micção/fisiologia , 1-(5-Isoquinolinasulfonil)-2-Metilpiperazina/farmacologia , Alcaloides , Animais , Benzofenantridinas , Inibidores Enzimáticos/farmacologia , Feminino , Injeções Intraventriculares , Potenciais da Membrana/efeitos dos fármacos , Agonistas Muscarínicos/farmacologia , Inibição Neural/efeitos dos fármacos , Oxotremorina/farmacologia , Fenantridinas/farmacologia , Proteína Quinase C/antagonistas & inibidores , Ratos , Ratos Sprague-Dawley , Micção/efeitos dos fármacosRESUMO
BACKGROUND: Cough receptor hypersensitivity is a fundamental feature of some conditions presenting with chronic non-productive cough. Suplatast tosilate, an anti-allergic agent, is a T helper (Th)2 cytokine inhibitor that inhibits the synthesis of interleukin (IL)-4, IL-5, immunoglobulin (Ig)E production, and local eosinophil accumulation. OBJECTIVE: The purpose of this study was to investigate the effect of suplatast on antigen-induced airway cough hypersensitivity and eosinophil infiltration into the airway. METHODS: Number of coughs elicited by inhalation of increasing concentrations of capsaicin (10-8, 10-6 and 10-4 M) was counted 24 h after an antigen challenge in conscious guinea-pigs and then bronchoalveolar lavage was performed. We investigated the effect of single (before antigen challenge or capsaicin provocation) or repetitive treatment with intraperitoneal suplatast at a dose of 10 or 30 mg/kg on antigen-induced cough hypersensitivity. RESULTS: Twenty-four hours after antigen challenge, guinea-pigs developed an increase in cough receptor sensitivity to inhaled capsaicin and eosinophil infiltration in the airways. After a 2-week treatment with suplatast, but not after only a single treatment before antigen challenge or capsaicin provocation, the antigen-induced early phase bronchoconstriction, cough hypersensitivity, and airway eosinophilia were inhibited in a dose-dependent manner. CONCLUSION: These results indicate that suplatast inhibits airway cough hypersensitivity underlying allergic eosinophilic inflammation.
Assuntos
Resistência das Vias Respiratórias/efeitos dos fármacos , Antialérgicos/uso terapêutico , Sulfonatos de Arila/uso terapêutico , Tosse/tratamento farmacológico , Hipersensibilidade Respiratória/tratamento farmacológico , Compostos de Sulfônio/uso terapêutico , Animais , Testes de Provocação Brônquica/efeitos adversos , Líquido da Lavagem Broncoalveolar/citologia , Broncoconstrição/efeitos dos fármacos , Modelos Animais de Doenças , Eosinófilos/efeitos dos fármacos , Cobaias , Japão , Masculino , Ovalbumina/efeitos adversos , Sensibilidade e Especificidade , Fatores de TempoRESUMO
Corticosteroids are widely used in bronchial asthma, but their mechanism of action is not fully understood. The in vitro studies have proposed that human T helper cells, type 1 (Th1) favor expression of CXCR3, whereas Th2 cells favor CCR4. In this study we investigated whether oral prednisolone modulates the balance of peripheral blood CXCR3+ and CCR4+ T cells. We analyzed the T-cell subsets in 28 patients with stable atopic asthma and 13 normal control subjects before and after 2 wk of treatment with prednisolone, 20 mg/d, or placebo in a randomized, double-blind, parallel group study. The numbers of CXCR3+ and CCR4+ memory T cells were measured with a flow cytometer, and expressed as percentages in CD4+/CD45RO+ memory T cells. In the steroid-treated asthma group, there was a decrease in CCR4+ T cells (from 29.3% to 20.3%, p < 0.0001), and an increase in CXCR3+/ CCR4+ ratio (from 1.86 to 2.89, p = 0.0047), whereas there was no change in CXCR3+ T cells. However, the percentages of CCR4+ cells did not change after steroid therapy in normal control subjects. These results suggest that short-term oral corticosteroid modulates the balances of CXCR3+ and CCR4+ cells in patients with asthma.
Assuntos
Anti-Inflamatórios/administração & dosagem , Asma/sangue , Asma/tratamento farmacológico , Prednisolona/administração & dosagem , Receptores de Quimiocinas/biossíntese , Linfócitos T/metabolismo , Administração Oral , Adolescente , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Receptores CCR4 , Receptores CXCR3RESUMO
The influence of muscarinic receptor stimulation and blockade on the central regulation of micturition was evaluated in conscious female rats. Saline was infused into the bladder to induce repeated bladder contractions and voiding. Increasing doses of a muscarinic agonist, oxotremorine-M (OXO-M; 0.01 to 1 microg/rat) or antagonist, atropine (0.1 to 30 microg/rat) were administered. Intrathecal OXO-M (0.1 microg) increased bladder capacity (BC; 85 +/- 17%), but did not change maximal voiding pressure (MVP), pressure threshold (PT), postvoiding intravesical pressure, or voiding efficiency (VE). Intracerebroventricular OXO-M (0.1 microg) increased BC (97 +/- 6%), MVP (45 +/- 19%), PT (158 +/- 49%), and reduced VE (-17 +/- 5%). A larger dose of OXO-M (1 microg, either i.c.v. or i.t.) produced greater changes. These effects were not reproduced by i.v. injections of OXO-M. The effects of OXO-M were blocked by pretreatment with atropine in a dose (1 microg i.c.v. or i.t.), which alone had no effect on voiding parameters. A larger dose of atropine (10 microg) reduced MP (-31 +/- 7% i.c.v. and -34 +/- 6% i.t.) and VE (-21 +/- 3% i.c.v. and -25 +/- 5% i.t.) but increased BC (52 +/- 8% i.c.v.). These results indicate that activation of muscarinic receptors in the brain or spinal cord can suppress voluntary voiding, but also stimulates bladder activity during bladder filling. The muscarinic inhibitory mechanisms do not appear to be tonically active. The effects of atropine (i.c.v. and i.t.) indicate that muscarinic excitatory mechanisms are tonically active. These findings raise the possibility that voiding function is regulated by both inhibitory and excitatory cholinergic mechanisms in the central nervous system.
Assuntos
Agonistas Muscarínicos/administração & dosagem , Antagonistas Muscarínicos/administração & dosagem , Oxotremorina/análogos & derivados , Receptores Muscarínicos/metabolismo , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/metabolismo , Micção/efeitos dos fármacos , Micção/fisiologia , Animais , Atropina/administração & dosagem , Encéfalo/efeitos dos fármacos , Encéfalo/fisiologia , Relação Dose-Resposta a Droga , Feminino , Injeções Intravenosas , Injeções Intraventriculares , Injeções Espinhais , Manometria , Contração Muscular/efeitos dos fármacos , Contração Muscular/fisiologia , Oxotremorina/administração & dosagem , Ratos , Medula Espinal/efeitos dos fármacos , Medula Espinal/fisiologiaRESUMO
BACKGROUND: Chronic desquamative eosinophilic bronchitis and bronchial hyperresponsiveness have been considered essential for bronchial asthma. However, it has not been studied whether airway eosinophils enhance or inhibit bronchial responsiveness in vivo. OBJECTIVE: This study was conducted to elucidate the influence of airway eosinophil accumulation on bronchial responsiveness in vivo. MATERIALS AND METHODS: Guinea pigs were transnasally treated with 75 microg/kg of polymyxin-B or vehicle twice a week for a total of 3 weeks. Guinea pigs were surgically cannulated and artificially ventilated 24 h after the last administration of polymyxin-B or vehicle. Ten minutes after the installation of artificial ventilation, ascending doses of methacholine, acetylcholine or histamine were inhaled for 20 s at intervals of 5 min. Subsequent study was conducted 20 min after treatment of 60 mg/kg of indomethacin in the same manner. Final study was conducted in naive guinea pigs after single inhalation of 75 microg/mL of polymyxin B. RESULTS: The proportion of eosinophils in bronchoalveolar lavage fluid significantly increased in guinea pigs treated with polymyxin-B compared with vehicle. Bronchial responsiveness to inhaled methacholine, acetylcholine and histamine was significantly decreased by the polymyxin-B treatment. This protective effect induced by polymyxin B was abolished by pretreatment of indomethacin. A significant increase in bronchial responsiveness was observed after a single inhalation of polymyxin B. CONCLUSION: These results suggest that in vivo airway eosinophils may reduce non-specific bronchial responsiveness through inhibitory or bronchoprotective prostanoids.
Assuntos
Hiper-Reatividade Brônquica/prevenção & controle , Eosinófilos/efeitos dos fármacos , Polimixina B/administração & dosagem , Acetilcolina/administração & dosagem , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Líquido da Lavagem Broncoalveolar/química , Broncoconstrição/efeitos dos fármacos , Broncoconstritores/administração & dosagem , Broncodilatadores/administração & dosagem , Eosinófilos/metabolismo , Cobaias , Histamina/administração & dosagem , Indometacina/uso terapêutico , Masculino , Cloreto de Metacolina/administração & dosagem , Modelos Animais , Polimixina B/uso terapêuticoRESUMO
A 66-year-old man was admitted to our hospital complaining of non-productive cough and low-grade fever. Chest X-ray examination revealed a mass shadow in the right hilum. Transbronchial lung biopsy of the tumor mass yielded a diagnosis of adenocarcinoma. Despite repeated chemotherapy using CDDP and VDS, metastasis to the right adrenal gland and right femur occurred, and was accompanied by hypercalcemia and hypophosphatemia. Serological study revealed elevated levels of PTH-rP and G-CSF. Six months after adenocarcinoma was diagnosed, multiple skin metastases of the cancer were observed. Immunohistochemical staining for PTH-rP and G-CSF indicated that production of cytokines had caused a paraneoplastic syndrome including hypercalcemia and leukocytosis. It appeared that the elevation of G-CSF was induced by IL-6 produced from PTH-rP in cancer tissue. Documentation of similar cases is required.
Assuntos
Adenocarcinoma/complicações , Hipercalcemia/etiologia , Leucocitose/etiologia , Neoplasias Pulmonares/complicações , Idoso , Fator Estimulador de Colônias de Granulócitos/sangue , Humanos , Masculino , Hormônio Paratireóideo/sangueRESUMO
1. Beta-adrenoceptor antagonists, such as propranolol, can provoke severe bronchoconstriction only in asthmatic subjects. Recently, we developed a guinea-pig model of propranolol-induced bronchoconstriction (PIB) and the purpose of this study was to investigate the role of alpha-adrenergic nerve pathways in this reaction. 2. Phentolamine administered after an antigen challenge did not inhibit PIB; however, its administration before the antigen challenge significantly inhibited the antigen-induced bronchoconstriction and also bronchoconstriction induced by methacholine inhalation. 3. We conclude that the alpha-adrenergic nerve system is not involved in the development of PIB following allergic reaction in our guinea-pig model.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Antígenos/farmacologia , Broncoconstrição/efeitos dos fármacos , Propranolol/farmacologia , Administração por Inalação , Animais , Broncoconstritores/farmacologia , Volume Expiratório Forçado/efeitos dos fármacos , Cobaias , Imunização Passiva , Técnicas In Vitro , Masculino , Cloreto de Metacolina/farmacologia , Ovalbumina/imunologia , Fentolamina/farmacologia , Respiração ArtificialRESUMO
Beta-adrenoreceptor antagonists, such as propranolol, can provoke severe bronchoconstriction in asthmatic subjects. Recently we developed an animal model of propranolol-induced bronchoconstriction and investigated the involvement of chemical mediators in this reaction. The purpose of this study was to elucidate the role of thromboxane A2 in the development of propranolol-induced bronchoconstriction after allergic bronchoconstriction. Passively sensitized guinea pigs were anesthetized and treated with diphenhydramine hydrochloride and were then artificially ventilated. Propranolol at a concentration of 10 mg/ml was inhaled 20 min after an aerosolized antigen challenge. A potent and selective thromboxane A2 synthase inhibitor, CS-518, in doses of 0.01, 0.1 and 1 mg/kg and vehicle were administered intravenously 15 min after the antigen challenge. Another study was performed in naive guinea pigs; ascending doses of methacholine (12.5, 25, 50, 100 and 200 microg/ml) were inhaled for 20 sec at 5-min intervals, 10 min after intravenous administration of CS-518. Propranolol inhaled 20 min after the antigen challenge caused bronchoconstriction in sensitized guinea pigs. CS-518 administered 15 min after the antigen challenge significantly inhibited propranolol-induced bronchoconstriction in a dose-dependent manner, while CS-518 did not influence the dose-dependent response to inhaled methacholine in naive guinea pigs. We conclude that thromboxane A2 contributes to the development of propranolol-induced bronchoconstriction following allergic reaction in our guinea pig model.
Assuntos
Antagonistas Adrenérgicos beta/farmacologia , Broncoconstrição/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Propranolol/antagonistas & inibidores , Tiofenos/farmacologia , Tromboxano-A Sintase/antagonistas & inibidores , Animais , Cobaias , Imunização Passiva , Masculino , Cloreto de Metacolina/farmacologia , Agonistas Muscarínicos/farmacologia , Propranolol/farmacologia , Respiração Artificial , Tromboxano A2/biossínteseRESUMO
It is unclear whether angiotensin II receptors are involved in bronchial hyperresponsiveness in asthmatic patients. We examined the effect of losartan, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in eight patients with stable asthma. Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV(1) (PC(20)-FEV(1)) and a 35% fall in standardized partial expiratory flow at 40% of FVC (PC(35)-PEF(40)), was measured on two occasions 2 wk apart. Losartan (50 mg once a day) or a placebo was orally administered for 1 wk before methacholine provocation test in a double-blind, randomized, crossover fashion. Although the PC(20)-FEV(1) values after placebo (2.037 [geometric standard error of the mean, GSEM = 0.210] mg/ml) and losartan (2.098 [GSEM, 0.239] mg/ml) were identical (p = 0.840), the geometric mean PC(35)-PEF(40) values significantly (p = 0.034) increased from 0.258 (GSEM, 0.156) mg/ml with placebo to 0.456 (GSEM, 0.186) mg/ml with losartan. We conclude that AT1 receptors are involved in bronchial hyperresponsiveness in asthmatic patients. This is the first report demonstrating the involvement of AT1 receptors in bronchial asthma.
Assuntos
Antagonistas de Receptores de Angiotensina , Asma/imunologia , Brônquios/efeitos dos fármacos , Brônquios/imunologia , Losartan/farmacologia , Cloreto de Metacolina/farmacologia , Adulto , Idoso , Asma/fisiopatologia , Estudos Cross-Over , Método Duplo-Cego , Feminino , Volume Expiratório Forçado , Humanos , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de AngiotensinaRESUMO
BACKGROUND AND STUDY AIMS: Gastric ulcer and hemorrhage are major complications in patients with chronic respiratory failure, but upper GI endoscopy tends to be avoided because of possible cardiopulmonary events. This study was designed to evaluate hypoxemia and subsequent cardiac complications during gastroscopic procedures in patients with chronic respiratory failure undergoing long-term home oxygen therapy (LHOT). PATIENTS AND METHODS: Gastroscopy was carried out in 10 patients undergoing LHOT and 10 age-matched control subjects without pulmonary diseases. Oxygen saturation and cardiac arrhythmias before and during gastroscopy were monitored. Patients were given 10 mg intramuscular scopolamine butylbromide and local anesthesia using 100-300 mg lidocaine gel 15 minutes before the procedure. Each patient continued to receive oxygen via a nasal cannula in the same dosage as their daily use. RESULTS: Decrease in oxygen saturation during endoscopic procedure was significantly greater in patients undergoing LHOT (from 95.9+/-0.9 to 93.4+/-1.7%) compared with control subjects (from 96.7+/-0.4 to 96.2+/-0.4%). There was a significant correlation between the degree of hypoxemia and the oxygen dosage required for their daily treatment in the patients (r = 0.727, P<0.02). CONCLUSIONS: These results indicate that the degree of respiratory failure influences the degree of decrease in oxygen saturation during gastroscopy. It is suggested that use of the nasal route for oxygen supply may be one of the major causes of the hypoxemia.
Assuntos
Arritmias Cardíacas/etiologia , Gastroscopia , Serviços de Assistência Domiciliar , Hipóxia/etiologia , Pneumopatias Obstrutivas/fisiopatologia , Oxigenoterapia , Idoso , Idoso de 80 Anos ou mais , Arritmias Cardíacas/fisiopatologia , Feminino , Humanos , Hipóxia/fisiopatologia , Pneumopatias Obstrutivas/terapia , Masculino , Oxigênio/sangue , Fatores de RiscoRESUMO
An inhalation of ultrasonically nebulized distilled water (UNDW) induces bronchoconstriction only in asthmatics, but the mechanism underlying the response is not fully understood. We have reported that bronchoconstriction occurs immediately after UNDW is inhaled 20 min after an antigen challenge in guinea pigs. Our aim was to examine the role of lipid mediators in this response. Passively sensitized guinea pigs were anesthetized and artificially ventilated. A sulfidopeptide leukotriene receptor antagonist, KCA-757, and platelet-activating factor antagonists, Y-24180 and E6123, were administered i.v. 15 min after an aerosolized antigen challenge, and UNDW was inhaled 5 min later. KCA-757, Y-24180, or E6123 did not, significantly alter the UNDW-induced bronchoconstriction. Together with our previous data that thromboxane A2 receptor antagonists did not influence the UNDW-induced bronchoconstriction, the present results suggest that lipid mediators are not involved in the UNDW-induced bronchoconstriction in our guinea pig model.
Assuntos
Broncoconstrição , Lipídeos/fisiologia , Animais , Broncoconstrição/efeitos dos fármacos , Cobaias , Antagonistas de Leucotrienos , Masculino , Modelos Biológicos , Nebulizadores e Vaporizadores , Fator de Ativação de Plaquetas/antagonistas & inibidores , Ultrassom , Água/administração & dosagemRESUMO
It has been proposed that acute eosinophilic pneumonia (AEP), which is characterized by the absence of recurrence, is associated with cigarette smoking (CS), because Japanese patients with AEP are young and have a high incidence of short-term smoking history. However, there has been no direct evidence that CS causes AEP. We hypothesized that tolerance might develop against repeated resumption of smoking cigarettes in CS-induced AEP cases. In this connection, we challenged a patient with CS-induced AEP with repeated resumption of CS, and it was demonstrated that CS induced AEP in conjunction with tolerance to repeated resumption of smoking.
Assuntos
Eosinofilia Pulmonar/etiologia , Fumar/efeitos adversos , Doença Aguda , Adulto , Antígenos/imunologia , Biópsia , Líquido da Lavagem Broncoalveolar/citologia , Diagnóstico Diferencial , Humanos , Masculino , Plantas Tóxicas , Eosinofilia Pulmonar/diagnóstico , Eosinofilia Pulmonar/fisiopatologia , Radiografia Torácica , Testes de Função Respiratória , Fumar/imunologia , Nicotiana/imunologiaRESUMO
BACKGROUND: Chronic airway eosinophil accumulation is characteristic of asthma. However, it remains unclear whether airway eosinophils enhance or reduce release of chemical mediators and/or action of the released mediators in the airways in vivo, because previous investigators have indicated that eosinophil-derived factors such as histaminase and arylsulfatase may alter the allergic reaction by metabolizing chemical mediators. Recently, we have developed a guinea pig model of propranolol-induced bronchoconstriction (PIB), which is mediated by lipid mediators such as thromboxane A2 (TxA2), cysteinyl leukotrienes (cLTs) and platelet activation factor (PAF). This study was conducted to explain the influence of airway eosinophil accumulation on antigen-induced bronchoconstriction and the following PIB, both of which are mediated by lipid mediators. METHODS: Guinea pigs were transnasally treated with 75 microg/kg of polymyxin-B or vehicle twice a week for a total of 3 weeks. Guinea pigs were anesthetized and treated with diphenhydramine hydrochloride, and then artificially ventilated 24 h after the last administration of polymyxin-B or vehicle followed by passive sensitization. Propranolol at a concentration of 10 mg/ml was inhaled 20 min after an aerosolized antigen challenge. RESULTS: The proportion of eosinophils in bronchoalveolar lavage fluid obtained 15 min after the propranolol inhalation was significantly increased in guinea pigs treated with polymyxin-B compared with the vehicle. The polymyxin-B treatment did not affect antigen-induced bronchoconstriction or the following PIB. CONCLUSIONS: We conclude that eosinophils accumulated in the airways by polymyxin-B does not affect release of chemical mediators induced by antigen or propranolol inhalation, or action of released mediators in vivo.
Assuntos
Antígenos/farmacologia , Broncoconstrição/efeitos dos fármacos , Eosinófilos/metabolismo , Propranolol/farmacologia , Sistema Respiratório/citologia , Administração por Inalação , Administração Intranasal , Animais , Asma/fisiopatologia , Broncoconstritores , Modelos Animais de Doenças , Cobaias , Lipídeos , Masculino , Cloreto de Metacolina/administração & dosagem , Camundongos , Polimixina B/administração & dosagem , Polimixina B/farmacologia , Sistema Respiratório/fisiopatologiaRESUMO
A case of a single ectopic vaginal ureter in a 6-year-old girl with urinary incontinence is reported. Excretory urography and renal sonography failed to visualize the dysplastic kidney, but enhanced computed tomography clearly demonstrated a poorly functioning hypoplastic kidney, ectopic ureter and vagina filled with contrast medium.
Assuntos
Coristoma/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Ureter , Doenças Vaginais/diagnóstico por imagem , Criança , Feminino , Humanos , Rim/anormalidades , Incontinência Urinária/etiologiaRESUMO
beta-adrenoreceptor blockers such as propranolol provoke bronchoconstriction only in asthmatic patients. Although cysteinyl leukotrienes (cLTs) and thromboxane A2 (TXA2) have been proposed to be involved in the pathophysiology of asthma, the role of these lipid mediators in propranolol-induced bronchoconstriction (PIB) has not been evaluated in asthmatics. This study was conducted to elucidate it. Nine patients with stable asthma, in whom a 20% or more decrease in FEV(1) occurred by inhalation of 20 mg/ml or less propranolol, participated in this study. A cLT antagonist, pranlukast (225 mg twice a day), a TXA2 antagonist, seratrodast (80 mg once a day), and placebo were orally given for 2 wk in a randomized and double-blinded manner. The provocative concentration of propranolol causing a 20% fall in FEV(1) (PC(20)) was determined on the last day of each 2-wk treatment. Pranlukast, but not seratrodast, tented to increase FEV(1) compared with placebo (2.14 +/- 0.29 versus 1.99 +/- 0.34 L, p = 0.0543). Pranlukast or seratrodast did not affect the PC(20) in comparison with placebo. We conclude that cLTs or TXA2 are not involved in PIB of asthmatics.
Assuntos
Antagonistas Adrenérgicos beta/farmacologia , Asma/fisiopatologia , Benzoquinonas/farmacologia , Broncoconstrição/efeitos dos fármacos , Cromonas/farmacologia , Ácidos Heptanoicos/farmacologia , Antagonistas de Leucotrienos/farmacologia , Propranolol/farmacologia , Tromboxano A2/antagonistas & inibidores , Adulto , Idoso , Broncoconstrição/fisiologia , Método Duplo-Cego , Feminino , Volume Expiratório Forçado/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Capacidade Vital/efeitos dos fármacosRESUMO
Administration of propranolol provokes bronchoconstriction only in asthmatic patients. It is unknown whether bronchodilator therapy can prevent the propranolol-induced bronchoconstriction (PIB). We previously reported an animal model of PIB in which bronchoconstriction is caused by propranolol when inhaled 20 minutes after an antigen provocation in passively sensitized guinea pigs. Our goal was to evaluate the bronchoprotective effects of bronchodilators on the PIB in our animal model. Propranolol was inhaled 20 minutes after an antigen challenge in passively sensitized, anesthetized, and artificially ventilated guinea pigs. Atropine (5 mg/kg) and equipotent doses of salbutamol (0.6 microgram/kg) and aminophylline (25 mg/kg), which were determined by the dose-response curves for inhibition of histamine-induced bronchoconstriction, were intravenously administered 5 minutes before the propranolol inhalation. Treatment of the animals with 25 mg/kg of aminophylline, but not with 0.6 microgram/kg of salbutamol or 5 mg/kg of atropine, significantly prevented the PIB. These results show that our animal model is an experimental model of PIB which is resistant to beta 2-agonists or anticholinergics and suggest that aminophylline may be useful to prevent and treat PIB resistant to beta 2-agonists.